PMC:7696151 / 41501-41772
Annnotations
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"1176","span":{"begin":169,"end":189},"obj":"Disease"},{"id":"1177","span":{"begin":191,"end":210},"obj":"Disease"},{"id":"1178","span":{"begin":220,"end":238},"obj":"Disease"}],"attributes":[{"id":"A1176","pred":"tao:has_database_id","subj":"1176","obj":"MESH:D001172"},{"id":"A1177","pred":"tao:has_database_id","subj":"1177","obj":"MESH:D008180"},{"id":"A1178","pred":"tao:has_database_id","subj":"1178","obj":"MESH:D012859"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Most of all, it showed immunosuppressive properties, allowing its employment (alone or in combination) in the first-line treatment of several auto-immune diseases, like rheumatoid arthritis, lupus erythematosus, primary Sjögren’s syndrome, and anti-phospholipid syndrome."}
LitCovid-PD-HP
{"project":"LitCovid-PD-HP","denotations":[{"id":"T55","span":{"begin":142,"end":162},"obj":"Phenotype"},{"id":"T56","span":{"begin":169,"end":189},"obj":"Phenotype"}],"attributes":[{"id":"A55","pred":"hp_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A56","pred":"hp_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/HP_0001370"}],"text":"Most of all, it showed immunosuppressive properties, allowing its employment (alone or in combination) in the first-line treatment of several auto-immune diseases, like rheumatoid arthritis, lupus erythematosus, primary Sjögren’s syndrome, and anti-phospholipid syndrome."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T269","span":{"begin":0,"end":271},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Most of all, it showed immunosuppressive properties, allowing its employment (alone or in combination) in the first-line treatment of several auto-immune diseases, like rheumatoid arthritis, lupus erythematosus, primary Sjögren’s syndrome, and anti-phospholipid syndrome."}